Get started
Author

Charlotte Gaskell

Observed name: Gaskell, Charlotte
ORCID: 0000-0002-6382-2277
Observed ORCID: 0000-0002-6382-2277
OpenAlex ID: A5012562971
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
2023 · Eleanor Barnes, Carl S. Goodyear, et al. · Nature Medicine · 141
PDF
Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)
2021 · Jennifer Pascoe, Aimee Jackson, et al. · BMC Cancer · 101
PDF
Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial
2021 · Pamela Kearns, Stefan Siebert, et al. · SSRN Electronic Journal · 64
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata
2023 · Penella J. Woll, Piers Gaunt, et al. · British Journal of Cancer · 15
PDF
Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]
2020 · Mark W. Drummond, Charlotte Gaskell, et al. · Blood · 13
AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)
2020 · Matthew J Ahearne, Charlotte Gaskell, et al. · Blood · 6
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
2025 · Graham McIlroy, Charlotte Gaskell, et al. · BMC Cancer · 5
PDF
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial
2024 · Graham McIlroy, Siân Lax, et al. · BMC Cancer · 5
PDF
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1
2025 · Gary Middleton, Charlotte Gaskell, et al. · Journal for ImmunoTherapy of Cancer · 3
Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial)
2025 · Ronjon Chakraverty, Emma Kempshall, et al. · BMJ Open · 2
PDF
Determining the recommended phase 2 dose (RP2D) of dose-intense irinotecan combined with IVA chemotherapy (I R IVA) in newly diagnosed very high risk rhabdomyosarcoma: A phase Ib study within the EpSSG Frontline and Relapsed Rhabdomyosarcoma study (FaR-RMS).
2025 · Hans Merks, Fitsum Ghebretinsea, et al. · Journal of Clinical Oncology · 1
PDF
Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice
2024 · Justin CT Loke, Charlotte Gaskell, et al. · Blood · 1
PDF
Defective T‐cell response to COVID ‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes
2023 · Justin Loke, Vinit Upasani, et al. · British Journal of Haematology · 1
PDF
A phase IIa study of the anti‐ PD ‐ L1 antibody avelumab in relapsed/refractory PTCL : The AVAIL ‐T trial
2026 · Matthew J. Ahearne, Matthew A. Timmins, et al. · British Journal of Haematology
PDF
The REFRACT trial: implementation of Bayesian power priors in a randomised, sequential phase II adaptive platform trial
2025 · Charlotte Gaskell, Kim Linton, et al. · BMC Medical Research Methodology
PDF
Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial
2025 · Robin J. Young, Amanda Kirkham, et al. · BMC Cancer
RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
2024 · Charlotte K Brierley, Charlotte Gaskell, et al. · Blood
Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone
2023 · Adam J Mead, Claire N Harrison, et al. · Blood
PDF
3031 – Chromothripsis and Leukemic Transformation in Mpn
2023 · Charlotte Brierley, Bon Ham Yip, et al. · Experimental Hematology
PDF
Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program
2021 · (Justin) Ching Ting Loke, Charlotte Gaskell, et al. · Blood
PDF
Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN
2020 · Charlotte K Brierley, Alba Rodriguez-Meira, et al. · Blood
Works count: 54
Citation count: 358
H-index: 6
I10-index: 5
Year
Topic
Type